Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Infliximab for the Treatment of Sterile Corneal Melt

Trial Profile

Topical Infliximab for the Treatment of Sterile Corneal Melt

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Corneal injuries
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 28 Apr 2026 Status changed from recruiting to completed.
  • 27 Jan 2021 Planned End Date changed from 31 Dec 2022 to 31 Dec 2027.
  • 27 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top